Multiple Myeloma, a disease of white blood cells, will claim 12,030 lives in 2025 (1.9% of all cancer deaths), according to estimates from the Surveillance, Epidemiology, and End Results (SEER) program. Another 36,110 new cases will be diagnosed in the same year, with African Americans having approximately double the incidence of myeloma compared to that of Americans of European ancestry. While recent improvements in treatment have resulted in a more favorable outlook for patients, five-year survival rates are still unacceptably low: 61%. The first solicitation for myeloma Specialized Program of Research Excellence (SPORE) applications was announced in 2001, applications were reviewed in 2002 and the first award given in 2003.
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
